Home
IMPACT PH Lecture Series
Education
Product Spotlight
PAH.tv Network
Slidesets and Resources
You are here :
PAH.tv Network
Login
|
Register
Please select a video from the list below.
New Therapies for Group 1 PAH
In this program, Drs. Vallerie McLaughlin, Ioana Preston and Rajan Saggar consider important findings from recent analyses from the landmark GRIPHON and SERAPHIN trials of selexipag and macitentan. The Phase 2 trial of the emerging IP receptor agonist ralinepag is discussed and the impact of PAH therapies on the quality of life of patients is reviewed in light of the TRACE study that examines patient perceptions of “well being”.
Recent Video
|
Most Viewed
Specialties :
<All Specialties>
Allied Health
Clinical Insights
Clinical Trials
Lecturer Bios
News
PAH
Search :
Transitioning Patients Between PH Therapies
Views - 230
Plasma BNP Predicts 5-Year Overall Survival in PAH
Views - 245
Are Direct Oral Anticoagulants Appropriate for PAH?
Views - 323
Options When Prostacyclin Side Effects are Unmanageable
Views - 323
SIOVAC: Sildenafil for PH after Mitral Valve Surgery
Views - 736
Macitentan in PH Due to LV Dysfunction: MELODY-1
Views - 386
Is Up-Front Triple Combination Therapy in PAH "A Thing"?
Views - 243
New Therapies for CTEPH
Views - 258
New Therapies for Group 1 PAH
Views - 313
How to Screen for PAH in Scleroderma-Spectrum Disorders
Views - 395
PAH-Related Morbidity Is Prognostic for Mortality
Views - 655
Pulmonary Hypertension Association Update
Views - 109
Getting Aggressive in PAH: Setting Goals and Escalating Care
Views - 522
Strategies for Transitioning Therapy in PAH
Views - 42
Palliative Care in PAH: Best Practice or Too Little, Too Late
Views - 39
Newer Medications and How To Use Them
Views - 70
Clinical Research Year in Review
Views - 55
Advances in Imaging for Lung Vasculature
Views - 37
Bleeding and Thrombosis After PTE
Views - 33
Serum CXC-Chemokine Ligand 10 is Associated with Severity of Chronic Thromboembolic Pulmonary Hypertension
Views - 19
NEDD9 is Upregulated By Hypoxia in Human Pulmonary Artery Endothelial Cells Selectively and Modulates Platelet-Endothelial Adhesion
Views - 21
Management of Severe Right Heart Failure in PTE Patients
Views - 22
The Imposters: What (almost) Everyone Thinks is CTEPH
Views - 17
Absence of the Factor V Leiden Mutation and Genetic Risk For CTEPH
Views - 25
Pulmonary Embolism, CTED and CTEPH: Connecting the Dots
Views - 15
Evaluation of CTEPH: VQ Scans and Planar Angiography
Views - 32
Patients with CTEPH Should Be Started on PAH Therapy Prior to PTE
Views - 16
An Overview of PH Directed Medical Therapy in CTEPH
Views - 37
CTED and the Value of Exercise Testing
Views - 12
Future Directions in CTEPH
Views - 23
Balloon Pulmonary Angioplasty for CTEPH: Patient Selection
Views - 19
CTEPH Patients Should NOT Be Started on PH Medical Therapy Before PTE
Views - 12
Mechanism of Lumen Enlargement and Pulmonary Injury In Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension
Views - 8
Distal Pulmonary Thromboendarterecomy: Is It Worth It?
Views - 9
Medical Decision in BPA
Views - 11
The Pursuit of Minimally Invasive Pulmonary Thromboendarterectomy
Views - 9
The Dilemma of CTEPH
Views - 76
Challenges of PAH in Heart Failure With Preserved Ejection Fraction
Views - 1009
Weighing Strategic Treatment Options in the Current Era of PAH Medicine
Views - 315
Expanding the Therapeutic Range of Current PAH Medications: What Next?
Views - 90
Selexipag for the Treatment of Connective Tissue Disease-Associated PAH
Views - 248
RESPITE Study Results
Views - 906
Assessing Risk in PAH Patients
Views - 568
When to Add or Switch Therapy
Views - 259
RESPITE: Evidence to Support a Switch Approach?
Views - 437
Switching from PDE-5 to sGC Stimulator
Views - 227
What is Tolerance to Therapy on PDE-5 or PGI-2?
Views - 196
What are the Choices When Escalating Therapy?
Views - 900
Parameters for Treatment Success
Views - 791
When Should Patients be Evaluated for Efficacy?
Views - 303
General Goals of Therapy for Patient on Monotherapy
Views - 421
Early Combination Therapy: Applying Aggressive Goals
Views - 138
Preventing Hospitalization in PAH Through Aggressive Early Therapy
Views - 167
Future Directions in PAH Therapy and Clinical Research
Views - 465
Quality of Life Issues in the Treatment of PAH
Views - 331
What Are the Risks to Combination Therapy?
Views - 74
Neurohormone in the Pathobiology of PH: Beta-blockers
Views - 62
Palliative Care in Pulmonary Arterial Hypertension
Views - 153
Oral Prostanoids for the Mgmt of PH: The Holy Grail or Beraprost Revisited?
Views - 268
Neurohormone in the pathobiology of PH: RAAS
Views - 43
Case Presentation: Palliative Care in PAH
Views - 23
Mitral Valve Disease and the Development of Pulmonary Arteriopathy
Views - 138
Vascular and Endothelial Biomarkers in PAH
Views - 50
Case of Atrial Septal Defect Associated with PH
Views - 1644
WHO Group II PH Due to Heart Failure w/Preserved Ejection Fraction
Views - 782
Case of a 58 Year Old with Scleroderma
Views - 444
Understanding the Diagnosis and Treatment of PAH
Views - 282
20 Years of Prostanoids: Spanning the Continuum of Care in PAH
Views - 683
Group 1 and Beyond: Case Studies in PH
Views - 220
Insights from Fetal Imaging
Views - 108
Pathophysiology of PH in the ICU
Views - 103
ICU Management of PH
Views - 141
Animal Models of PH
Views - 69
Novel Endothelial Targets
Views - 56
Treatment of Angioproliferative PAH
Views - 37
Privacy
|
Terms Of Use
|
Contact Us
|
Copyright 2018 by PAH.tv
|
About PAH.tv